We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan
· Delayed Price · Currency is TWD 34.30
-0.10 (-0.29%)
May 16, 2025, 1:30 PM CST
We Can Medicines Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -70.41 | -47.18 | 14.8 | 100.05 | 38.79 | 42.71 |
| Depreciation & Amortization | 313.57 | 306.87 | 274.49 | 252.03 | 212.89 | 197.28 |
| Other Amortization | 2.21 | 2.21 | 1.69 | 1.52 | 0.87 | 0.28 |
| Loss (Gain) From Sale of Assets | 4.04 | 0.14 | 2.77 | 7.2 | 1.85 | 1.1 |
| Asset Writedown & Restructuring Costs | 4.32 | 4.4 | 2 | 3.68 | - | -0.86 |
| Loss (Gain) From Sale of Investments | -0.37 | -0.37 | - | -0.11 | -0.19 | - |
| Stock-Based Compensation | 3.9 | 5.07 | 9.98 | 4.11 | - | - |
| Provision & Write-off of Bad Debts | 1.04 | -0.12 | -2.4 | 3.94 | 0.1 | -0.06 |
| Other Operating Activities | 13.7 | 18.93 | 22.92 | 39.92 | 14.38 | 13.5 |
| Change in Accounts Receivable | 58.87 | 47.61 | -83.48 | -14.72 | -54.84 | -34.13 |
| Change in Inventory | -31.15 | -74.06 | -86.76 | -106.48 | -54.09 | -31.69 |
| Change in Accounts Payable | -51.4 | -30.94 | 27.28 | 77.89 | 150.23 | 29.76 |
| Change in Unearned Revenue | -0.09 | 0.79 | -3.43 | -1.63 | -1.97 | -0.54 |
| Change in Other Net Operating Assets | -2.44 | 26.94 | -40.03 | -20.84 | -1.04 | 11.72 |
| Operating Cash Flow | 246.16 | 260.68 | 139.84 | 346.67 | 457.16 | 79.05 |
| Operating Cash Flow Growth | 10.43% | 86.41% | -59.66% | -24.17% | 478.31% | - |
| Capital Expenditures | -48.34 | -63.95 | -92.55 | -122.54 | -339.58 | -58 |
| Sale of Property, Plant & Equipment | 0.31 | 0.31 | - | - | - | - |
| Sale (Purchase) of Intangibles | -4.09 | -5.29 | -1.4 | -0.38 | -3.37 | -3.05 |
| Other Investing Activities | 1.52 | -0.11 | -4.5 | -5.53 | -2.81 | -4.16 |
| Investing Cash Flow | -50.6 | -69.04 | -98.45 | -128.45 | -345.76 | -65.21 |
| Short-Term Debt Issued | - | 555 | 1,050 | 265 | 6 | 135 |
| Long-Term Debt Issued | - | - | - | - | 150 | - |
| Total Debt Issued | 135 | 555 | 1,050 | 265 | 156 | 135 |
| Short-Term Debt Repaid | - | -690 | -915 | -265 | -6 | -150 |
| Long-Term Debt Repaid | - | -238.09 | -211.89 | -188.45 | -164.98 | -157.31 |
| Total Debt Repaid | -524.57 | -928.09 | -1,127 | -453.45 | -170.98 | -307.31 |
| Net Debt Issued (Repaid) | -389.57 | -373.09 | -76.89 | -188.45 | -14.98 | -172.31 |
| Issuance of Common Stock | 19.44 | 356.37 | - | - | - | 197.21 |
| Common Dividends Paid | -12 | -12 | - | - | - | - |
| Other Financing Activities | -14.75 | -17.78 | -20.23 | -16.88 | -13.23 | -12.26 |
| Financing Cash Flow | -396.88 | -46.5 | -97.12 | -205.32 | -28.21 | 12.65 |
| Net Cash Flow | -201.32 | 145.15 | -55.73 | 12.9 | 83.18 | 26.49 |
| Free Cash Flow | 197.82 | 196.73 | 47.29 | 224.13 | 117.58 | 21.05 |
| Free Cash Flow Growth | 46.27% | 316.03% | -78.90% | 90.63% | 458.55% | - |
| Free Cash Flow Margin | 6.09% | 6.02% | 1.51% | 6.79% | 4.21% | 0.79% |
| Free Cash Flow Per Share | 4.44 | 4.53 | 1.12 | 5.37 | 2.94 | 0.66 |
| Cash Interest Paid | 27.43 | 27.43 | 23.45 | 19.06 | 14.37 | 13.26 |
| Cash Income Tax Paid | 5.63 | 5.63 | 6.72 | - | - | - |
| Levered Free Cash Flow | 175.6 | 156.69 | -2.81 | 141.92 | -72.62 | - |
| Unlevered Free Cash Flow | 192.01 | 173.84 | 11.86 | 153.84 | -63.6 | - |
| Change in Net Working Capital | 30.74 | 39.82 | 195.31 | 54.14 | -46.64 | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.